{
    "genomic_alterations": [
      {
        "name": "KRAS mutation",
        "type": "Oncogene mutation",
        "effect": "Antagonistic",
        "clinical_implication": "Reduces efficacy of BRAF inhibitors; typically mutually exclusive with BRAF V600E",
        "frequency_of_cooccurrence": "Rare (<1%)"
      },
      {
        "name": "PIK3CA mutation",
        "type": "Oncogene mutation",
        "effect": "Synergistic",
        "clinical_implication": "May contribute to resistance to BRAF inhibitors; combination therapy targeting both pathways may be beneficial",
        "frequency_of_cooccurrence": "10-15% of BRAF-mutant CRC"
      },
      {
        "name": "Microsatellite Instability (MSI-H)",
        "type": "Molecular phenotype",
        "effect": "Variable",
        "clinical_implication": "MSI-H tumors with BRAF V600E may respond better to immunotherapy than MSS BRAF-mutant tumors",
        "frequency_of_cooccurrence": "~30% of BRAF-mutant CRC"
      }
    ]
  }
  